Moleculin Biotech Inc. (NASDAQ: MBRX) announced that an abstract featuring cardiac safety data for its drug candidate Annamycin has been accepted for poster presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago from May 29 to June 2.

The abstract presents pooled cardiac safety analyses from clinical trials evaluating Annamycin in patients with acute myeloid leukemia and soft tissue sarcoma. The data covers 90 patients treated across five completed clinical trials, with source-verified cardiac assessments available for 78 patients.

The analysis showed a median cumulative Annamycin dose of 660 mg/m2, with most doses exceeding conventional lifetime anthracycline limits. The study found no statistically significant change in left ventricular ejection fraction from baseline to final assessment, with a mean difference of -0.12%. No correlation was observed between cumulative dose and cardiac function changes, or between patient age and cardiac function changes.

The poster will be presented on May 30, 2026, from 1:30 PM to 4:30 PM CDT in a session focused on Symptom Science and Palliative Care.

Annamycin is designed to avoid multidrug resistance mechanisms while potentially eliminating cardiotoxicity associated with currently prescribed anthracyclines. The company is conducting the MIRACLE trial, a pivotal Phase 3 study evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia.

Previously reported results from the company's Phase 1b/2 study showed a 50% complete remission rate and 60% composite complete remission rate, with median overall survival of 12.39 months in the intent-to-treat population.